Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Exubera in Diabetes
NCT00143247Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2003
- Primary completion
- Jan 2008
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of insulin human in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoints: Forced Expiratory Volume in 1 Second at 126 months and Carbon Monoxide Diffusing Capacity at 126 months. Started Mar 2003; status: terminated.
02
Drugs
insulin human
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00143247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143247.